Active Ingredient History
Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C. The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 2/Phase 3)
Breast Neoplasms, Male (Phase 1)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Colorectal Neoplasms (Phase 1)
Esophageal Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Hepacivirus (Phase 1)
Hepatitis C (Phase 1/Phase 2)
HIV Infections (Phase 1)
Liver Neoplasms (Phase 1/Phase 2)
Melanoma (Phase 1)
Neoplasms (Phase 1)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1/Phase 2)
Stomach Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue